The DCs are pulsed with synthetic peptides based on the HER2/neu sequence that are capable of sensitizing helper T cells in most individuals [422,423], and Th1 responses are associated with good clinical outcomes in breast cancer [424]. Here, ERBB2 is linked to breast carcinoma.